Video

Study: Effects of two dosing regimens of Netarsudil in patients with Fuchs corneal dystrophy

Author(s):

Sheryl Stevenson
Conferences|ASCRS

Richard L. Lindstrom, MD, of Minnesota Eye Consultants, discusses his ASCRS presentation, "Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy," with Ophthalmology Times' Sheryl Stevenson.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Foundation Fighting Blindness joins University of Colorado Anschutz Medical Campus and leading institutions receive funding to fast track whole eye transplantation program
December 4th 2024

Foundation Fighting Blindness joins University of Colorado Anschutz Medical Campus and leading institutions receive funding to fast track whole eye transplantation program

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis
November 1st 2024

AAO 2024: Ocular imaging in the emergency department can provide timely, accurate diagnosis

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function
October 22nd 2024

Life Biosciences reports advances in nonhuman primate studies on partial epigenetic reprogramming for restoring visual function

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD
October 21st 2024

AAO 2024: New drug shows promise as first to protect vision in patients with dry AMD

© 2024 MJH Life Sciences

All rights reserved.